This document provides methods and materials for treating hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g.,
kidney stone
disease). For example, methods and materials for using one or more compounds that can activate
oxalate transport to treat a
mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g.,
kidney stone
disease) are provided. In some cases, one or more of
atorvastatin,
cinacalcet,
cyproheptadine,
vortioxetine, pizotifen,
ritonavir,
dronedarone, thioridazine,
nilotinib,
bexarotene,
mebendazole,
racecadotril,
pefloxacin,
cabazitaxel, oxibendazole, pyridostigmine,
olanzapine, trifluoperazine, AZ-5104, centrimonium,
cladribine,
ponatinib,
dasatinib, and
erlotinib can be administered to a
mammal (e.g., a human) having hyperoxalemia, hyperoxaluria, and / or one or more diseases, disorders, and / or conditions associated with hyperoxalemia and / or hyperoxaluria (e.g.,
kidney stone
disease) to treat the
mammal.